相关实验视频
Updated: May 22, 2026

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
用免疫调节剂pentoxifylline治疗缺血性心肌病:随机研究结果
Karen Sliwa1, Angela Woodiwiss, Veuvette N Kone
1Department of Cardiology, Chris-Hani Baragwanath Hospital, Johannesburg, South Africa.
Circulation
|February 19, 2004
概括
托西菲林改善了心脏功能,并减少了缺血性心肌病患者的炎症标志物. 这种心力衰竭治疗改善了临床状态和喷射率,提供了新的治疗途径.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性免疫激活在心力衰竭中很常见,可以使病情恶化.
- 研究免疫调节剂可能为心力衰竭提供新的治疗策略.
- 托西菲林是一种免疫调节剂,在心血管疾病中具有潜在的益处.
研究的目的:
- 为了确定pentoxifylline是否能改善缺血性心肌病患者的左心室功能.
- 评估托西菲林对炎症标志物,预后标志物和亡标志物的影响.
- 评估pentoxifylline作为心力衰竭标准护理的辅助疗法.
主要方法:
- 一项前性,随机,双盲,安慰剂控制的研究.
- 38名患有缺血性心肌病的患者接受了托西菲林或安慰剂6个月.
- 评估的临床评估,放射性核素腹腔镜学,心声学和血液分析.
主要成果:
- 托西菲林改善了功能类,缩血压和左心室喷射率.
- 观察到C-反应蛋白 (CRP),NT-pro BNP,瘤坏死因子-α (TNF-α) 和Fas/Apo-1的显著减少.
- 与安慰剂组相比,pentoxifylline组发生的死亡人数较少.
结论:
- 托西菲林改善了心力衰竭患者的临床状态和心脏功能,这些患者患有缺血性左心室功能障碍.
- 用托西菲林治疗导致炎症,预后和亡标志物的血水平降低.
- 托西菲林是治疗缺血性心肌病的标准疗法的一个有前途的补充.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

